StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration
April 23, 2018 8:14 AM
Nomura/Instinet reiterated a Buy rating and $420.00 price target on Biogen (NASDAQ: BIIB) following the company's announced details of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q
April 24, 2018 8:48 AM
Biogen (BIIB) Tops Q1 EPS by 13c, Miss on Revenues
April 24, 2018 7:00 AM
Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN Meetings
April 23, 2018 7:33 AM
New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants
April 23, 2018 7:30 AM
SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction
April 20, 2018 12:05 PM
Biogen (BIIB) option implied volatility elevated into Q1
April 20, 2018 11:53 AM
Pre-Open Movers 04/20: (LLNW) (IONS) (PF) (GE) Higher; (CLW) (SKX) (TEAM) Lower (more...)
April 20, 2018 9:23 AM
Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug Development
April 20, 2018 6:37 AM
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
April 20, 2018 6:30 AM
